Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL5802491 | 0.98 | KDM4E (0.34) | KDM4EALDH1A1HPGDGLAGAA | |
| Thioguanine SCHEMBL5051774 | 0.76 | PNP (0.43) | KDM4EALDH1A1HPGDHSD17B10TP53 | |
| SCHEMBL1590661 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL2968460 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL30480257 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL840561 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL2009845 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL11486221 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL5748053 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL4323514 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1HPGDGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758613-B2 | Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INTSTITUTES OF HEALTH (US) | 2020-09-01 | — | — | US | claimed |
| US-20170112926-A1 | COMBINATION THERAPIES USING ANTI-METABOLITES AND AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | 2017-04-27 | — | — | US | claimed |
| WO-2015191617-A2 | COMBINATION THERAPIES USING ANTI-METABOLITES AND AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| US-8383605-B2 | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals | AETERNA ZENTARIS GMBH (DE) | 2013-02-26 | — | — | US | claimed |
| US-20110028421-A1 | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals | AETERNA ZENTARIS GMBH (DE) | 2011-02-03 | — | — | US | claimed |
| US-6841710-B2 | Instant degradation of plastics into soluble non-toxic products | ROSEN OREN (IL) | 2005-01-11 | — | — | US | claimed |
| US-20040064005-A1 | Instant degradation of plastics into soluble non-toxic products | ROSEN OREN (IL) | 2004-04-01 | — | — | US | claimed |
| US-20020156333-A1 | Instant degradation of plastics into soluble non-toxic products | ROSEN OREN (IL) | 2002-10-24 | — | — | US | claimed |
| WO-2002062924-A1 | INSTANT DEGRADATION OF PLASTICS TO SOLUBLE NON-TOXIC PRODUCTS | ROSEN OREN (IL) | 2002-08-15 | — | — | WO | claimed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4108248-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES INC (US) | 2025-03-13 | — | — | US | disclosed |
| EP-0005200-B1 | SILVER HALIDE PHOTOGRAPHIC MATERIAL AND METHOD OF PREPARATION | Agfa-Gevaert AG (DE) | 1981-04-15 | — | — | EP | disclosed |
| US-4198237-A | GERMANIUM SULFIDE | FUJI PHOTO FILM CO., LTD. (JP) | 1980-04-15 | — | — | US | disclosed |
| US-4197124-A | SILVER OR COPPER AND SULFUR, SELENIUM OR TELLURIUM0 | FUJI PHOTO FILM CO., LTD. (JP) | 1980-04-08 | — | — | US | disclosed |
| US-4177072-A | HYDROPHILIC AND OLEOPHILIC AREAS | FUJI PHOTO FILM CO., LTD. (JP) | 1979-12-04 | — | — | US | disclosed |
| EP-0005200-A2 | Silver halide photographic material and method of preparation | Agfa-Gevaert AG (DE) | 1979-11-14 | — | — | EP | disclosed |
| US-3968226-A | 3-Heterocyclic thiomethylcephalosporins as antibacterial agents | SMITHKLINE CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | KDM4E 4194/4885ALDH1A1 781/4885HPGD 539/4885 |
| US-20020156333-A1 | Instant degradation of plastics into soluble non-toxic products | REL, STRA6, RARA | KDM4E 1774/4885ALDH1A1 1143/4885HPGD 837/4885 |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | MKI67, HCCS, NCF1 | KDM4E 3726/4885ALDH1A1 1340/4885HPGD 1940/4885 |
| US-20110028421-A1 | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals | PHOSPHO1, PMM2, ENPP2 | KDM4E 2569/4885ALDH1A1 2423/4885HPGD 2980/4885 |
| US-20040064005-A1 | Instant degradation of plastics into soluble non-toxic products | RARA, REL, STRA6 | KDM4E 1846/4885ALDH1A1 1147/4885HPGD 843/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | KDM4E 1730/4885ALDH1A1 1923/4885HPGD 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.